Journals / Ege Klinikleri Tıp Dergisi / 2021 / Cilt: 59 - Sayı: 1

Male Breast Cancer Single Center Experience: Analysis of Clinical Features and Oncological Out comes

Erkek Meme Kanseri Tek Merkez Deneyimi: Klinik Özelliklerin ve Onkolojik Sonuçların Analizi

Pages
1–5
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Clinical and pathological data, surgical treatment procedures and overall survival data of the patients were analyzed retrospectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Even though male breast cancer is responsible for less than 1% of all male cancers, its prognosis proceeds as poor.
📊
Key Findings & Data:Method: Male patients who underwent surgical treatment for breast cancer in the clinic between January 2011 and November 2020 were included in the study.
💡
Conclusion & Impact:Clinical and pathological data, surgical treatment procedures and overall survival data of the patients were analyzed retrospectively.
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Even though male breast cancer is responsible for less than 1% of all male cancers, its prognosis proceeds as poor. Since male breast cancer is rare, information about the disease is limited. In this study, we aimed to present the clinical, pathological features and clinical experiences of male breast cancer cases. Method: Male patients who underwent surgical treatment for breast cancer in the clinic between January 2011 and November 2020 were included in the study. Clinical and pathological data, surgical treatment procedures and overall survival data of the patients were analyzed retrospectively. Results:The median mean age of a total of 16 patients included in the study was 63.6 years. Invasive ductal carcinoma (87.5%) was the most common histological type. Only one patient was triple negative. The most common type was luminal A (50%) and the most common was stage 1A (31.3%). Modified radical mastectomy wasperformed in 8 patients (87.5%).

Özet

Amaç: Erkek meme kanseri tüm erkek kanserlerinin% 1'inden daha azından sorumlu olsa da prognozu kötü seyretmektedir. Erkek meme kanseri nadir olduğu için hastalıkla ilgili bilgiler sınırlıdır. Bu çalışmada erkek meme kanseri vakalarının klinik, patolojik özelliklerini ve klinik deneyimlerini sunmayı amaçladık. Gereç ve Yöntem: Ocak 2011-Kasım 2020 tarihleri arasında kliniğimizde meme kanseri nedeniyle cerrahi tedavi gören erkek hastalar çalışmaya dahil edildi. Hastaların klinik ve patolojik verileri, cerrahi tedavi prosedürleri ve genel sağkalım verileri geriye dönük olarak analiz edildi. Bulgular: Çalışmaya dahil edilen toplam 16 hastanın medyan yaş ortalaması 63,6 yıldı. İnvazif duktal karsinom (% 87.5) en sık görülen histolojik tipti. Sadece bir hasta triple negatifti. En sık görülen tip luminal A (% 50) ve en sık görülen evre 1A (% 31.3) idi. Sekiz hastaya (% 87,5) modifiye radikal mastektomi yapıldı. Aksiller lenf nodu metastazı 8 hastada tespit edildi. En yaygın patolojik evre 1A (% 31,3) idi. Dört hasta neoadjuvan tedavi aldı ve 9 hasta adjuvan tedavi aldı. Yine 9 hasta postoperatif radyoterapi almıştı. Medyan takip süresi 15 hasta için 54 aydır (en az 6 - en çok 118 ay). Takip sırasında 3 (% 18,8) hasta öldü. Beş yıllık sağkalım oranı% 78.6 olarak bulundu. Sonuç: Erkek meme kanserlerinin tedavisi ile ilgili bilgiler sınırlıdır. Kabul edilebilir hayatta kalma süreleri multimodal tedavi yaklaşımları ile sağlanır. Bu hormonal pozitif tümör grubunda hormonoterapiler ön plana çıkmaktadır. Erkek meme kanseri için spesifik bir tedavi protokolü belirlemek için farklı merkezlerden gelen veriler derlenmeli ve gözden geçirilmelidir.

🔖

Cite This Article

TOPAL, U., ERDOĞAN, O., PARLAKGÜMÜŞ, A., TURAN, Ü., TAŞ, Z. A., İRKÖRÜCÜ, O. (2022). Male Breast Cancer Single Center Experience: Analysis of Clinical Features and Oncological Out comes. Ege Klinikleri Tıp Dergisi, Cilt: 59 - Sayı: 1, 1–5. https://ajindex.com/articles/495610

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Ozmen V. Breast cancer in Turkey: clinical and histopathological characteristics ( Anaysis of 13,240 Patients ). J Breast Health 2014; 10(2): 98-105. 2:Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. 3:Niewoehner CB, Schorer AE. Gynaecomastia and breast cancer in men. BMJ2008;336(7646):709-13. 4:Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann InternMed 2002; 137: 678-87. 5:Yadav S, Karam D, Bin Riaz, I et al. Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer 2020;126(1): 26-36. 6:Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018; 29: 405‐ 17. 7:Bystricky B, Kohutek, F, Rosik A. Male breast cancer-a single center experience. Oncology letters, 2016;12(2): 1615-19. 8:Soliman M, Hetnał, M. Male breast cancer: a clinicopathological study of an Egyptian population (Alexandria experience). Contemporary Oncology 2016;20(4): 335. 9:O’Brien KM, Cole SR, Tse CK et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010;16;6100-10. 10:Shaaban, A. M. Pathology of the male breast. Diagnostic Histopathology, 2019;25(4):138-42. 11:Yalaza M, İnan, A,Bozer, M. Male breast cancer. The journal of breast health, 2016;12(1): 1-8 12:Howlader N, Noone AM, Krapcho M et al. SEER cancer statistics review, 1975–2014. 2017, National Cancer Institute: Bethesda, MD 13:Uslukaya Ö, Gümüş M, Gümüş H, Bozdağ Z, Türkoğlu A. The Management and Outcomes of Male Breast Cancer. The journal of breast health, 2016;12(4): 165-70 14:Broman K K, Joya L, Sun W et al. Utility of Taking Additional Margins When Performing Breast-Conserving Surgery with Intraoperative Radiation Therapy for Early Breast Cancer. World Journal of Surgery, 2020;44(10): 3410-3416 15:Gök M, Topal U, Öz B, Akgün H, Akcan A C, Sözüer E M. Comparison of Clinical Features and Treatment Results of Mix Mucinous Carcinomas and Other Atypical Carcinomas of the Breast. European Journal of Breast Health, 2019;15(4):222-28. 16:Özkurt E, Tükenmez M, Yılmaz R et al. Favorable long-term outcome in male breast cancer. European journal of breast health, 2018;14(3):180-5 17: WalsheJ. M, Berman A W, Vatas Uet al. A prospective study of adjuvant CMF in males with node positive breast